Zacks Research Lowers Earnings Estimates for OPKO Health

OPKO Health, Inc. (NASDAQ:OPK) – Equities research analysts at Zacks Research reduced their Q2 2026 EPS estimates for shares of OPKO Health in a research note issued to investors on Tuesday, May 19th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.07). The consensus estimate for OPKO Health’s current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for OPKO Health’s Q4 2026 earnings at ($0.08) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at ($0.18) EPS.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The company had revenue of $124.20 million for the quarter, compared to the consensus estimate of $130.51 million. During the same quarter in the previous year, the firm posted ($0.10) EPS. The business’s revenue was down 17.1% compared to the same quarter last year.

OPK has been the topic of several other research reports. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $1.55.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.23 on Thursday. The firm’s 50-day moving average is $1.16 and its 200-day moving average is $1.25. OPKO Health has a 52-week low of $0.98 and a 52-week high of $1.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.17 and a current ratio of 3.61. The company has a market cap of $928.76 million, a price-to-earnings ratio of -4.56 and a beta of 1.42.

Institutional Trading of OPKO Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in OPKO Health by 80.0% in the 1st quarter. Bank of America Corp DE now owns 1,141,849 shares of the biotechnology company’s stock valued at $1,302,000 after buying an additional 507,590 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in OPKO Health in the 1st quarter valued at $125,000. State of Wyoming acquired a new stake in OPKO Health in the 1st quarter valued at $190,000. First Trust Advisors LP acquired a new stake in OPKO Health in the 1st quarter valued at $570,000. Finally, Fifth Third Bancorp acquired a new stake in OPKO Health in the 1st quarter valued at $147,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.